Bulletin
Investor Alert

Dec. 7, 2019, 4:20 p.m. EST

HEXO LOSS NOTICE: Rosen Law Firm Reminds HEXO Corp. Investors of Important Deadline in Securities Class Action - HEXO

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    HEXO Corp. (HEXO)

or Cancel Already have a watchlist? Log In

NEW YORK, Dec 07, 2019 (GLOBE NEWSWIRE via COMTEX) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of HEXO Corp. /zigman2/quotes/206508254/composite HEXO -8.99% between January 25, 2019 and November 15, 2019, inclusive (the "Class Period") of the important January 27, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Hexo investors under the federal securities laws.

To join the Hexo class action, go to http://www.rosenlegal.com/cases-register-1734.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Hexo's reported inventory was misstated as the Company was failing to write down or write off obsolete product that no longer had value; (2) Hexo was engaging in channel-stuffing in order to inflate its revenue figures and meet or exceed revenue guidance provided to investors; (3) Hexo was cultivating cannabis at its facility in Niagara, Ontario that was not appropriately licensed by Health Canada; and (4) as a result, Hexo's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 27, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1734.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ .

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

lrosen@rosenlegal.com

pkim@rosenlegal.com

cases@rosenlegal.com

www.rosenlegal.com

__GNW8366DE3E__IMG

(C) Copyright 2019 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/206508254/composite
US : U.S.: NYSE
$ 1.62
-0.16 -8.99%
Volume: 10.71M
Jan. 17, 2020 6:30p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$457.70 million
Rev. per Employee
N/A
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.